Article

In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients

2025-05-24

Abstract excerpt

<h4>Background</h4> Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates vary widely between subgroups, with an average overall survival of 70%. Recurrent medulloblastoma is highly aggressive, treatment-resistant, and usually fatal. In addition, current treatments are highly toxic to the developing brain and surviving patients suffer from lifelong side effects. Therefore, novel thera...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4749ab71-8918-518e-808c-fb07f7297332
DOI: 10.1101/2025.05.23.655845

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patientsDOI 10.1101/2025.05.23.655845Read

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.Semantic proximity Read

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Semantic proximity Read

Medulloblastoma: Molecular Classification-Based Personal Therapeutics.Semantic proximity Read

Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a TimeSemantic proximity Read

Emerging treatments and gene expression profiling in high-risk medulloblastoma.Semantic proximity Read

An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.Semantic proximity Read

Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological responseSemantic proximity Read

Integrative multi-omics combined with functional pharmacological profiling in patient-derived organoids identifies personalized therapeutic vulnerabilities of adult high-grade gliomasSemantic proximity Read

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaSemantic proximity Read

The impact of molecularly matched treatment and tumor mutational burden on pediatric brain tumor patient outcomesSemantic proximity Read

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity Read

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).Semantic proximity Read